Traws Pharma, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Iain D. Dukes
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 12 Penns Trail Newtown PA United States of America 18940
- IPO Date
- Jul 25, 2013
- CIK
- 0001130598
- Website
- trawspharma.com
- Similar Companies
- Business
- Traws Pharma, Inc. (NASDAQ: TRAW) is a clinical-stage biopharmaceutical company that develops small-molecule oral product candidates for respiratory viral diseases and cancer; its antiviral pipeline includes Ratutrelvir (TRX01), a ritonavir-independent main protease (Mpro/3CL protease) inhibitor for COVID-19 and Long COVID, and Tivoxavir marboxil, a cap-dependent endonuclease inhibitor for bird flu and seasonal influenza with activity against resistant strains; its oncology portfolio features narazaciclib, a proprietary multi-targeted kinase inhibitor including CDK4/6 for solid tumors such as refractory endometrial and metastatic breast cancer as well as hematological malignancies in monotherapy or combination, and rigosertib for various cancers alone or combined with other therapies. The company maintains license agreements with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University to support its programs. Traws Pharma, formerly Onconova Therapeutics, Inc., changed its name in April 2024 following a business combination with Trawsfynydd Therapeutics, Inc. and raised $14 million in private placement financing from OrbiMed and Torrey Pines to advance clinical catalysts including narazaciclib studies; in December 2024, it secured up to $72.6 million in equity financing from investors including Perceptive Advisors, OrbiMed, Alyeska, Torrey Pines, and Ikarian Capital, with an initial $20 million tranche extending cash runway into first-half 2026 and additional tranches tied to bird flu and Phase 2A data readouts. Founded in 1998 and headquartered in Newtown, Pennsylvania, Traws Pharma operates primarily in the United States with a focus on vulnerable patient populations through accelerated clinical strategies emphasizing safety and simple dosing.
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
Traws Pharma (NASDAQ:TRAW) Shares Up 8.8% – Should You Buy?
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript
Traws Pharma Reports Second Quarter 2025 Results and Business Highlights
Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib